Market Overview

Janney Buys Into KemPharm Ahead Of 'Transformative' Summer Catalyst

Janney Buys Into KemPharm Ahead Of 'Transformative' Summer Catalyst

KemPharm Inc (NASDAQ: KMPH) has struggled to gain traction since its 2015 initial public offering, but one long-sidelined analyst is ready for action.

The Rating

Janney analyst Ken Trbovich initiated coverage of KemPharm with a Buy and $17 price target.

The Thesis

Janney anticipates a “transformative catalyst” in the late June or early July release of Phase 3 data on a new ADHD therapy.

“For years, I tracked KemPharm as it struggled to eventually gain FDA approval of its first prodrug for pain, but we expect value creating events are coming soon from its efforts to develop a prodrug version of d-methylphenidate for treating ADHD,” Trbovich said in a Wednesday note. 

Considering the prodrug’s previously demonstrated efficacy, the analyst calculated high odds of positive Phase 3 outcomes.

If approved, the treatment could become the first ADHD stimulant bearing an abuse-deterrent label given its positive and upcoming results in comparative studies for “drug liking." 

For Trbovich, the only point of caution for KemPharm is its balance sheet.

“While we see this as being of little concern if the data is positive, it could be extremely challenging if it is not." 

Price Action

KemPharm shares were up 8.2 percent at the time of publication midday Wednesday. 

Related Links:

KemPharm Spikes On FDA Approval Of Apadaz

Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching

Latest Ratings for KMPH

Sep 2019DowngradesBuyNeutral
Jun 2019Initiates Coverage OnBuy
May 2018Initiates Coverage OnBuy

View More Analyst Ratings for KMPH
View the Latest Analyst Ratings

Posted-In: Janney. Ken TrbovichAnalyst Color Health Care Price Target Initiation Analyst Ratings General Best of Benzinga


Related Articles (KMPH)

View Comments and Join the Discussion!

Latest Ratings

PNRJefferiesInitiates Coverage On
IPHIBank of AmericaMaintains80.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Eurozone Flash PMIs See Further Deterioration In The Economic Activity

EUR/USD Forecast: 3 Reasons Pushing The Pair To A 6-month Low